References Barbara G De Giorgio R Stanghellini V Cremon C Salvioli B

References barbara g de giorgio r stanghellini v

This preview shows page 3 - 6 out of 7 pages.

References Barbara, G., De Giorgio, R., Stanghellini, V., Cremon, C., Salvioli, B., & Corinaldesi, R. (2004). New pathophysiological mechanisms in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 20 (2), 1-9. doi:10.1111/j.1365-2036.2004.02036.x Clayburgh, D. R., Shen, L., & Turner, J. R. (2004). A porous defense: The leaky epithelial barrier in intestinal disease. Laboratory Investigation; a Journal of Technical Methods and Pathology, 84( 3), 282-291.
Image of page 3
Huether, S. E., & McCance, K. L. (2017). Understanding pathophysiology (6th ed.). St. Louis, MO: Mosby Michielan, A., & D'Incà, R. (2015). Intestinal permeability in inflammatory bowel disease: Pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators of Inflammation, 2015 (628157). doi:10.1155/2015/628157 Saha, L. (2014). Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence- based medicine. World Journal of Gastroenterology, 20 (22), 6759-6773. doi:10.3748/wjg.v20.i22.6759 First Response Hi Nkemdili, Precise and interesting post. I found out that articles are recommending the use of placebo analgesia as a treatment for irritable bowel syndrome. Placebo treatment can have a significant impact on subjective complaints (Miller & Colloca, 2009). Pain is a complex, multifaceted phenomenon, and the literature indicates that individual expectations can alter how the central nervous system responds to painful stimuli. Given the complexity of pain, endogenous pain modulation must engage multiple systems to generate and maintain a placebo analgesic response. Furthermore, recent studies have shown measurable physiological changes in response to placebo treatment that could explain how placebos alter symptoms. A crucial question is establishing how physicians and other providers can take optimal advantage of placebo effects consistent with their responsibility to foster patient trust and obtain informed consent (Finniss, Kaptchuk, Miller, & Benedetti, 2010). An ethical problem is created since to be
Image of page 4
beneficial in clinical practice placebos require deception, but this violates the moral principles of respect for patient autonomy and informed consent. References Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010). Placebo effects: Biological, clinical and ethical advances. Lancet 375, 686-695. Miller, F. G., & Colloca, L. (2009). The legitimacy of placebo treatments in clinical practice: Evidence and ethics. American Journal of Bioethics 9, 39-47. Second Response Hi Bola, Interesting post. I found a few works of literature on the effect of inflammatory bowel disease and psych disorders. Research reveals that inflammatory bowel disease (IBD) comprising Crohn's disease and ulcerative colitis involves increased frequency of mental disorders (Nowakowski, Chrobak, & Dudek, 2016). Inflammatory bowel disease (IBD) predisposes a risk of developing anxiety, low mood or depression, which is the most common. However, some
Image of page 5
Image of page 6

You've reached the end of your free preview.

Want to read all 7 pages?

  • Fall '17
  • keisha lovence
  • Gastroenterology, Irritable bowel syndrome, Ulcerative colitis, Inflammatory bowel disease, bowel disease

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture